flutamide has been researched along with Cancer of Liver in 13 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The growth of hepatocellular carcinoma (HCC) is thought to be dependent on androgens, as androgen receptors are present in most of these tumors." | 6.71 | Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. ( , 2004) |
| "Flutamide is an androgen receptor (AR) antagonist approved by the United States Food and Drug Administration for the treatment of prostate cancer." | 5.42 | Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1. ( Bisson, WH; Jang, HS; Kerkvliet, NI; Koch, DC; Kolluri, SK; Kopparapu, PR; O'Donnell, EF; Punj, S, 2015) |
| "The growth of hepatocellular carcinoma (HCC) is thought to be dependent on androgens, as androgen receptors are present in most of these tumors." | 2.71 | Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. ( , 2004) |
| "Flutamide is an androgen receptor (AR) antagonist approved by the United States Food and Drug Administration for the treatment of prostate cancer." | 1.42 | Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1. ( Bisson, WH; Jang, HS; Kerkvliet, NI; Koch, DC; Kolluri, SK; Kopparapu, PR; O'Donnell, EF; Punj, S, 2015) |
| "DHT promotes the hepatoma formation in vivo nude mice through PEG10 activation." | 1.34 | Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. ( Boquan, J; Chaoqun, L; Dehua, Y; Feili, G; Hui, W; Jian, Q; Jie, X; Jinquan, T; Lang, C; Luokun, X; Qiuping, Z; Yanping, J; Yi, S; Youxin, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Höfner, T | 1 |
| Vallet, S | 1 |
| Hadaschik, BA | 1 |
| Pahernik, S | 1 |
| Duensing, S | 1 |
| Hohenfellner, M | 1 |
| Jäger, D | 1 |
| Grüllich, C | 1 |
| Koch, DC | 1 |
| Jang, HS | 1 |
| O'Donnell, EF | 1 |
| Punj, S | 1 |
| Kopparapu, PR | 1 |
| Bisson, WH | 1 |
| Kerkvliet, NI | 1 |
| Kolluri, SK | 1 |
| Corrie, P | 1 |
| Mayer, A | 1 |
| Shaw, J | 1 |
| D'Ath, S | 1 |
| Blagden, S | 1 |
| Blesing, C | 1 |
| Price, P | 1 |
| Warner, N | 1 |
| Farla, P | 1 |
| Hersmus, R | 1 |
| Trapman, J | 1 |
| Houtsmuller, AB | 1 |
| Jie, X | 1 |
| Lang, C | 1 |
| Jian, Q | 1 |
| Chaoqun, L | 1 |
| Dehua, Y | 1 |
| Yi, S | 1 |
| Yanping, J | 1 |
| Luokun, X | 1 |
| Qiuping, Z | 1 |
| Hui, W | 1 |
| Feili, G | 1 |
| Boquan, J | 1 |
| Youxin, J | 1 |
| Jinquan, T | 1 |
| Lin, CJ | 1 |
| Hsieh, RK | 1 |
| Lim, KH | 1 |
| Chen, HH | 1 |
| Cheng, YC | 1 |
| Wu, CJ | 1 |
| Manesis, EK | 1 |
| Giannoulis, G | 1 |
| Zoumboulis, P | 1 |
| Vafiadou, I | 1 |
| Hadziyannis, SJ | 1 |
| Newling, DW | 1 |
| Denis, L | 2 |
| Vermeylen, K | 1 |
| Chao, Y | 1 |
| Chan, WK | 1 |
| Huang, YS | 1 |
| Teng, HC | 1 |
| Wang, SS | 1 |
| Lui, WY | 1 |
| Whang-Peng, J | 1 |
| Lee, SD | 1 |
| Sylvester, RJ | 1 |
| de Voogt, H | 1 |
| Martelli, A | 1 |
| Campart, GB | 1 |
| Carrozzino, R | 1 |
| Ghia, M | 1 |
| Mattioli, F | 1 |
| Mereto, E | 1 |
| Orsi, P | 1 |
| Puglia, CP | 1 |
| Liang, L | 1 |
| Lu, M | 1 |
| Huang, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081] | Phase 2 | 58 participants (Anticipated) | Interventional | 2019-12-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for flutamide and Cancer of Liver
| Article | Year |
|---|---|
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flutamide; Gemci | 2002 |
Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplasti | 2004 |
Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
Topics: Analysis of Variance; Androgens; Carcinoma, Hepatocellular; Double-Blind Method; Drug Therapy, Combi | 1995 |
Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Flutamide; Goserelin; Humans; Liver | 1993 |
Phase II study of flutamide in the treatment of hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma, Hepatocellular; Female; | 1996 |
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 1998 |
7 other studies available for flutamide and Cancer of Liver
| Article | Year |
|---|---|
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic C | 2015 |
Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1.
Topics: Androgen Antagonists; Carcinoma, Hepatocellular; Cell Proliferation; Flutamide; Hep G2 Cells; Humans | 2015 |
Antiandrogens prevent stable DNA-binding of the androgen receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Blotting, Western; Carcino | 2005 |
Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells.
Topics: Androgen Antagonists; Animals; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Northern; Blottin | 2007 |
Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2007 |
Evaluation of flutamide genotoxicity in rats and in primary human hepatocytes.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Azoxymethane; Colon; Colonic Neoplas | 2000 |
[Antiandrogen treatment for nude mice model with ectopic transplanted human HCC].
Topics: Androgen Antagonists; Animals; Carcinoma, Hepatocellular; Flutamide; Humans; Liver Neoplasms; Male; | 1998 |